FDA D.I.S.C.O. Burst Edition: FDA approvals of Jemperli (dostarlimab-gxly) for patients with mismatch repair deficient recurrent or advanced solid tumors, and Opdivo (nivolumab) for the adjuvant treatment of patients with urothelial carcinoma
0:00
6:00
Listen to a soundcast of the August 17, 2021, and August 19, 2021, FDA approvals of Jemperli (dostarlimab-gxly) for patients with mismatch repair deficient recurrent or advanced solid tumors, and Opdivo (nivolumab) for the adjuvant treatment of patients with urothelial carcinoma
Mais episódios de "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"
Não percas um episódio de “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)” e subscrevê-lo na aplicação GetPodcast.